Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Accumulated Expenses for 5 consecutive years, with $19.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $19.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.3 million, a N/A change, with the full-year FY2024 number at $23.6 million, changed N/A from a year prior.
  • Accumulated Expenses was $19.3 million for Q3 2025 at Caribou Biosciences, down from $23.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.6 million in Q4 2024 to a low of $100.0 in Q3 2021.
  • A 4-year average of $14.5 million and a median of $14.9 million in 2022 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 46.39% in 2021; the steepest drop was 46.39% in 2021.
  • Caribou Biosciences' Accumulated Expenses stood at $13.1 million in 2021, then grew by 13.5% to $14.9 million in 2022, then soared by 58.42% to $23.6 million in 2024, then dropped by 18.08% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Accumulated Expenses are $19.3 million (Q3 2025), $23.6 million (Q4 2024), and $19.0 million (Q1 2024).